State of New Jersey Common Pension Fund D Sells 775 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

State of New Jersey Common Pension Fund D trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 46,483 shares of the company’s stock after selling 775 shares during the period. State of New Jersey Common Pension Fund D owned about 0.06% of IDEXX Laboratories worth $25,800,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Global Retirement Partners LLC increased its position in shares of IDEXX Laboratories by 12.8% during the 3rd quarter. Global Retirement Partners LLC now owns 344 shares of the company’s stock worth $149,000 after purchasing an additional 39 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in IDEXX Laboratories by 335.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 1,850 shares of the company’s stock valued at $809,000 after acquiring an additional 1,425 shares in the last quarter. Oak Thistle LLC grew its holdings in shares of IDEXX Laboratories by 46.9% during the third quarter. Oak Thistle LLC now owns 830 shares of the company’s stock valued at $363,000 after buying an additional 265 shares in the last quarter. Harvey Investment Co. LLC boosted its stake in IDEXX Laboratories by 4.4% during the 3rd quarter. Harvey Investment Co. LLC now owns 53,458 shares of the company’s stock valued at $23,376,000 after purchasing an additional 2,235 shares during the period. Finally, Czech National Bank raised its holdings in shares of IDEXX Laboratories by 47.6% in the 3rd quarter. Czech National Bank now owns 14,508 shares of the company’s stock worth $6,344,000 after buying an additional 4,682 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded down $5.02 during mid-day trading on Thursday, reaching $489.24. 358,456 shares of the company’s stock were exchanged, compared to its average volume of 430,629. The firm has a market capitalization of $40.63 billion, a price-to-earnings ratio of 49.08, a price-to-earnings-growth ratio of 3.80 and a beta of 1.26. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. The firm has a 50-day moving average price of $533.74 and a two-hundred day moving average price of $510.50.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.05 earnings per share. Analysts predict that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on IDXX shares. The Goldman Sachs Group raised their target price on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a report on Tuesday, January 30th. Finally, Barclays increased their price target on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $591.50.

Insider Buying and Selling

In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP George Fennell sold 8,198 shares of the stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock valued at $24,871,960. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.